C12Y 117/01004
Xanthine dehydrogenase
Official title: Xanthine dehydrogenase (1.17.1.4)
C12Y117/01004 (Xanthine dehydrogenase) appears on 5 US grants and 9 published applications in this corpus.
Search patents in C12Y- Granted patents
- 5
- Published applications
- 9
- Assignees
- 7
- Inventors
- 23
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2022 | 1 | 1 |
| 2023 | 2 | 4 |
| 2024 | 0 | 1 |
| 2025 | 0 | 2 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inhibiting XDH expression18 Aug 2026US 12,709,752 B2Novo Nordisk A/S
- RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use19 May 2026US 12,630,826 B2Arrowhead Pharmaceuticals, Inc.
- RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use18 Apr 2023US 11,629,349 B2Arrowhead Pharmaceuticals, Inc.
- RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use10 Jan 2023US 11,549,112 B1Arrowhead Pharmaceuticals, Inc.
- Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof10 May 2022US 11,326,166 B1Alnylam Pharmaceuticals, Inc.
- Compositions and methods for inhibiting xdh expression26 Feb 2026US 2026/0055414 A1Novo Nordisk A/S
- Compositions and methods of modulating xanthine dehydrogenase25 Sep 2025US 2025/0295688 A1Horizon Therapeutics Ireland DAC
- Combination, therapeutic uses and prophylactic uses25 Sep 2025US 2025/0295739 A1Quantec Limited
- Clostridium autoethanogenum with enhanced growth rate4 Apr 2024US 2024/0110149 A1Alliance for Sustainable Energy, LLC
- RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use4 May 2023US 2023/0139166 A1Arrowhead Pharmaceuticals, Inc.
Most cited
By later US patents
- Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof2US 11,326,166 B1Alnylam Pharmaceuticals, Inc. · 2022
- RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use2US 11,629,349 B2Arrowhead Pharmaceuticals, Inc. · 2023
- RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use1US 11,549,112 B1Arrowhead Pharmaceuticals, Inc. · 2023